Trial Profile
A study evaluating triple combination of statin, evolocumab and eicosapentaenoic acid in patients with high cardiovascular risk.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 27 Sep 2017
Price :
$35
*
At a glance
- Drugs Evolocumab (Primary) ; Atorvastatin; Eicosapentaenoic acid
- Indications Carotid stenosis; Heart failure; Myocardial infarction
- Focus Therapeutic Use
- 27 Sep 2017 New trial record
- 30 Aug 2017 Results presented at the ESC Congress 2017: Annual Congress of the European Society of Cardiology